Pharvaris (NASDAQ:PHVS) Trading Up 9.1% – Should You Buy?

Pharvaris N.V. (NASDAQ:PHVS)’s share price shot up 9.1% on Wednesday . The stock traded as high as $26.18 and last traded at $26.23. 109,299 shares changed hands during mid-day trading, a decline of 48% from the average session volume of 208,701 shares. The stock had previously closed at $24.05.

Wall Street Analysts Forecast Growth

PHVS has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Wednesday, October 8th. Morgan Stanley increased their price objective on Pharvaris from $37.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, December 4th. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research note on Wednesday, December 3rd. Leerink Partners set a $38.00 target price on Pharvaris in a research report on Wednesday, December 3rd. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, November 19th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.56.

Pharvaris Trading Up 3.6%

The stock has a market cap of $1.35 billion, a P/E ratio of -8.07 and a beta of -2.79. The firm’s fifty day moving average is $24.99 and its 200 day moving average is $23.01.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.08. Research analysts forecast that Pharvaris N.V. will post -2.71 earnings per share for the current fiscal year.

Institutional Trading of Pharvaris

A number of hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. bought a new stake in shares of Pharvaris in the third quarter valued at about $75,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new position in shares of Pharvaris in the second quarter valued at $57,000. JPMorgan Chase & Co. boosted its stake in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares in the last quarter. Public Employees Retirement System of Ohio increased its holdings in Pharvaris by 39.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 6,269 shares of the company’s stock valued at $156,000 after buying an additional 1,769 shares during the period. Finally, Alliancebernstein L.P. bought a new stake in Pharvaris in the 3rd quarter valued at $224,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.